Semaglutide is a GLP-1 receptor agonist used for physician-supervised weight management. Tirzepatide is a dual GLP-1/GIP receptor agonist with greater average weight loss in clinical trials. Both require physician evaluation and prescription. Compounded versions are available at significantly lower cost than branded options. The right choice depends on individual health history, goals, and physician evaluation.
GLP-1 receptor agonists have fundamentally changed the landscape of physician-supervised weight management. Originally developed for type 2 diabetes management, semaglutide and tirzepatide have demonstrated unprecedented efficacy for weight loss in clinical trials — and their use in men's health optimization has grown rapidly.
For men dealing with excess body fat — particularly the visceral adiposity associated with low testosterone and metabolic syndrome — GLP-1 therapy can be a clinically meaningful component of a comprehensive optimization protocol.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the action of the naturally occurring GLP-1 hormone, which is released after eating. Semaglutide reduces appetite, slows gastric emptying, and improves insulin sensitivity. It is available as a weekly subcutaneous injection (Ozempic, Wegovy) or as a daily oral tablet.
In the STEP trials, weekly semaglutide (2.4 mg) produced an average weight loss of 14.9% of body weight over 68 weeks in non-diabetic adults with obesity. Compounded semaglutide is available at a fraction of the cost of branded options.
Tirzepatide is a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism produces greater appetite suppression and metabolic effects than GLP-1 agonism alone.
In the SURMOUNT-1 trial, tirzepatide (15 mg weekly) produced an average weight loss of 20.9% of body weight over 72 weeks — the largest average weight loss demonstrated in a pharmaceutical trial for obesity at the time of publication. Compounded tirzepatide is available at significantly lower cost than branded Mounjaro or Zepbound.
| Factor | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Average weight loss (clinical trials) | ~15% body weight | ~21% body weight |
| Administration | Weekly injection or daily oral | Weekly injection or daily oral |
| Branded options | Ozempic, Wegovy | Mounjaro, Zepbound |
| Compounded availability | Yes | Yes |
| Branded cost (monthly) | ~$950–$1,000 | ~$950–$1,000 |
| Compounded cost (monthly) | $90–$260 | $140–$340 |
| Side effects | Nausea, GI effects | Nausea, GI effects (similar profile) |
| Physician evaluation required | Yes | Yes |
GLP-1 medications require physician evaluation and prescription. Standard clinical criteria include:
Men with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are contraindicated for GLP-1 therapy. Physician evaluation of health history and labs is required before prescribing.
For men who want the metabolic benefits of GLP-1 therapy without the full appetite suppression effect — or who are sensitive to side effects — microdosing protocols (starting at very low doses and titrating slowly) are available. Redline RX physicians evaluate each patient's goals and tolerance to determine the appropriate starting dose and titration schedule.
Visceral fat accumulates aromatase, the enzyme that converts testosterone to estrogen. Men with significant abdominal adiposity often have suppressed testosterone as a direct result. GLP-1-mediated weight loss can improve testosterone levels independently of TRT — and for men on TRT, reducing visceral fat improves the hormonal environment and may reduce estrogen-related side effects.
The choice between semaglutide and tirzepatide depends on your physician's evaluation of your health history, metabolic goals, and tolerance. In general:
Semaglutide is appropriate for men who are new to GLP-1 therapy, have a target weight loss of 10–15%, or prefer a more established clinical track record.
Tirzepatide is appropriate for men with more significant weight loss goals (15–25%+), or those who have not achieved adequate results with semaglutide.
Both are available through Redline RX as physician-prescribed monthly protocols. Join the waitlist at getredlinerx.com.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. All treatments require evaluation and a valid prescription from a licensed, board-certified physician. Results may vary. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved and have not been reviewed for safety, effectiveness, or manufacturing quality by the FDA. Medically reviewed by Redline RX Medical Advisory Team — April 15, 2026.